FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Novalis LifeSciences Investments II GP, LLC		 2. Date of Event Requiring Statement (MM/DD/YYYY)
6/5/2023 

 3. Issuer Name and Ticker or Trading Symbol

Telesis Bio Inc. [TBIO]
(Last)        (First)        (Middle)

1 LIBERTY LANE E, SUITE 112		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          ___X___ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

HAMPTON, NH 03842      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Redeemable Convertible Preferred Stock  (1) (1)Common Stock 6558625 (1)$2.3633 I See footnotes (3)(4)
Warrant (right to buy) 6/5/2023 6/5/2030 Common Stock 6558626 (2)$2.5996 I See footnotes (3)(4)
Warrant (right to buy) 6/5/2023 6/5/2025 Common Stock 3279313 (2)$2.5996 I See footnotes (3)(4)
Explanation of Responses:
(1) Each share of Redeemable Convertible Preferred Stock has a stated value of $100 (the "Stated Value") and accrues dividends daily at an initial rate of 8.0% per annum. The Stated Value, as adjusted to give effect to such dividends, is referred to as the "Accrued Value." Each share of Redeemable Convertible Preferred Stock is convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, into a number of shares of the Issuer's Common Stock determined by dividing the Accrued Value by the conversion price. The Redeemable Convertible Preferred Stock is not convertible to the extent that such conversion would result in the holder of such Redeemable Convertible Preferred Stock, together with its attribution parties, beneficially owning in excess of 19.99% of the Issuer's voting power.
(2) The warrants are not exercisable to the extent that such exercise would result in the holder of such warrant, together with its attribution parties, beneficially owning in excess of 19.99% of the Issuer's voting power.
(3) Represents securities held directly by Novalis LifeSciences Investments II, L.P. ("Novalis LifeSciences"). Novalis LifeSciences Investments II GP, LLC ("Novalis LifeSciences GP"), whose managers are Marijn Dekkers and Paul Meister, is the general partner of Novalis LifeSciences. As a result, Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister may each be deemed to share voting and dispositive power with respect to the securities held by Novalis LifeSciences. Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
(4) Mr. Meister is a director of the issuer.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Novalis LifeSciences Investments II GP, LLC
1 LIBERTY LANE E, SUITE 112
HAMPTON, NH 03842
X

Novalis LifeSciences Investments II, L.P.
1 LIBERTY LANE E, SUITE 112
HAMPTON, NH 03842
X

MEISTER PAUL M
1 LIBERTY LANE E, SUITE 112
HAMPTON, NH 03842		XX

DEKKERS MARIJN E
1 LIBERTY LANE E, SUITE 112
HAMPTON, NH 03842
X
Signatures
Novalis LifeSciences Investments II GP, LLC, By: /s/ Paul M. Meister, Title: Authorized Signatory6/8/2023
**Signature of Reporting PersonDate

Novalis LifeSciences Investments II, L.P., By: Novalis LifeSciences Investments II GP, LLC, its general partner, By: /s/ Paul M. Meister, Title: Authorized Signatory6/8/2023
**Signature of Reporting PersonDate

/s/ Paul M. Meister6/8/2023
**Signature of Reporting PersonDate

/s/ Marijn E. Dekkers6/8/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Codex DNA Charts.
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Codex DNA Charts.